Ekso Bionics (NASDAQ:EKSO) Coverage Initiated at StockNews.com

Stock analysts at StockNews.com started coverage on shares of Ekso Bionics (NASDAQ:EKSO) in a note issued to investors on Monday. The firm set a “hold” rating on the stock.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $9.00 price target on shares of Ekso Bionics in a report on Tuesday, January 14th.

Ekso Bionics Price Performance

Ekso Bionics stock opened at $0.48 on Monday. The firm has a market cap of $10.48 million, a P/E ratio of -0.73 and a beta of 1.46. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.14 and a current ratio of 2.81. The business’s fifty day moving average is $0.61 and its two-hundred day moving average is $0.82. Ekso Bionics has a 52 week low of $0.37 and a 52 week high of $1.78.

Ekso Bionics (NASDAQ:EKSO) last announced its quarterly earnings results on Monday, March 3rd. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.07). Ekso Bionics had a negative return on equity of 83.09% and a negative net margin of 62.95%. The business had revenue of $5.09 million during the quarter, compared to the consensus estimate of $5.05 million. Equities research analysts forecast that Ekso Bionics will post -0.48 earnings per share for the current fiscal year.

Ekso Bionics Company Profile

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.